| Autor: |
Luis Piñana, José, Vazquez, Lourdes, Heras, Inmaculada, Francesco Aiello, Tommaso, López-Corral, Lucia, Arroyo, Ignacio, Soler-Espejo, Eva, García-Cadenas, Irene, Garcia-Gutierrez, Valentín, Aroca, Cristina, Chorao, Pedro, Olave, María T., Lopez-Jimenez, Javier, Acera Gómez, Marina, Arellano, Elena, Cuesta-Casas, Marian, Avendaño-Pita, Alejandro, González-Santillana, Clara, Ángel Hernández-Rivas, José, Roldán-Pérez, Alicia |
| Předmět: |
|
| Zdroj: |
Frontiers in Oncology; 2024, p1-18, 18p |
| Abstrakt: |
Introduction: Scarce real-life data exists for COVID-19 management in hematologic disease (HD) patients in the Omicron era. Purpose: To assess the current clinical management and outcome of SARS-CoV-2 infection diagnosed, identify the risk factors for severe outcomes according to the HD characteristics and cell therapy procedures in a real-world setting. Methods: A retrospective observational registry led by the Spanish Transplant Group (GETH-TC) with 692 consecutive patients with HD from December 2021 to May 2023 was analyzed. Results: Nearly one-third of patients (31%) remained untreated and presented low COVID-19-related mortality (0.9%). Nirmatrelvir/ritonavir was used mainly in mild COVID-19 cases in the outpatient setting (32%) with a low mortality (1%), while treatment with remdesivir was preferentially administered in moderate-tosevere SARS-CoV-2 infection cases during hospitalization (35%) with a mortality rate of 8.6%. The hospital admission rate was 23%, while 18% developed pneumonia. COVID-19-related mortality in admitted patients was 14%. Older age, autologous hematopoietic stem cell transplantation (SCT), chimeric antigen receptor T-cell therapy, corticosteroids and incomplete vaccination were factors independently associated with COVID-19 severity and significantly related with higher rates of hospital admission and pneumonia. Incomplete vaccination status, treatment with prior anti-CD20 monoclonal antibodies, and comorbid cardiomyopathy were identified as independent risk factors for COVID-19 mortality. Conclusions: The results support that, albeit to a lower extent, COVID-19 in the Omicron era remains a significant problem in HD patients. Complete vaccination (3 doses) should be prioritized in these immunocompromised patients. The identified risk factors may help to improve COVID-19 management to decrease the rate of severe disease, ICU admissions and mortality. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
